曲美他嗪在经皮冠状动脉介入治疗后的疗效与安全性(ATPCI):一项随机、双盲、安慰剂对照试验
ATPCI是一项在27个国家365个中心进行的随机、双盲、安慰剂对照、事件驱动试验,纳入6007例21-85岁、因稳定心绞痛择期PCI或因不稳定心绞痛或非ST段抬高型心肌梗死紧急PCI后30天内成功血供重建的患者,随机接受口服曲美他嗪35 mg缓释片每日两次或匹配安慰剂。中位随访47.5个月,主要复合终点(心源性死亡、因心脏事件住院、需增加/换用/加量至少一种抗心绞痛药的心绞痛复发或持续、需冠状动脉造影的心绞痛复发或持续)在曲美他嗪组700例(23.3%)与安慰剂组714例(23.7%)间无显著差异(HR 0.98,95%CI 0.88-1.09,p=0.73)。各组分终点及按择期/紧急PCI分层分析结果一致,严重治疗中出现的不良事件两组相似(40.9% vs 41.1%)。作者结论认为,成功PCI后常规使用曲美他嗪不影响心绞痛复发或结局,长期处方未见统计学显著安全性担忧。
要点
- 成功PCI后接受最佳药物治疗的患者,长期口服曲美他嗪35 mg缓释片每日两次未减少主要复合终点事件(23.3% vs 23.7%,HR 0.98,95%CI 0.88-1.09,p=0.73)。
- 主要终点各组分(心源性死亡、心脏事件住院、需调整抗心绞痛药的心绞痛、需冠脉造影的心绞痛)在两组间均无显著差异。
- 按择期PCI或紧急PCI(不稳定心绞痛或非ST段抬高型心肌梗死)分层,结果与总体一致。
- 严重治疗中出现的不良事件发生率曲美他嗪组40.9% vs 安慰剂组41.1%,关注的不良事件频率两组相似。
- 作者认为,临床实践中考虑曲美他嗪的地位时应顾及这些结果;长期处方在该研究人群中未见统计学显著安全性担忧。
适用人群与场景
- 年龄21-85岁,因稳定心绞痛行择期PCI,或因不稳定心绞痛或非ST段抬高型心肌梗死行紧急PCI,且随机化前30天内成功完成PCI的患者。
- 来自欧洲、南美、亚洲和北非27个国家365个中心。
- 所有患者均接受标准循证药物治疗作为背景治疗。
处置流程与药物剂量
- 口服曲美他嗪35 mg缓释片每日两次,或匹配安慰剂,长期使用(中位随访47.5个月)。
- 背景治疗为标准循证药物治疗。
研究设计与关键结果
- 随机、双盲、安慰剂对照、事件驱动试验,纳入6007例患者,曲美他嗪组2998例,安慰剂组3009例。
- 中位随访47.5个月(IQR 42.3-53.3),主要终点事件曲美他嗪组700例(23.3%)vs 安慰剂组714例(23.7%),HR 0.98(95%CI 0.88-1.09),p=0.73。
- 主要终点各组分单独分析两组间均无显著差异;按择期或紧急PCI分层结果相似。
- 严重治疗中出现的不良事件:曲美他嗪组2983例中1219例(40.9%)vs 安慰剂组2990例中1230例(41.1%);关注的不良事件频率两组相似。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照、事件驱动试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,成功PCI后接受最佳药物治疗的患者常规长期使用曲美他嗪不影响心绞痛复发或结局,临床实践中考虑曲美他嗪的地位时应顾及这些结果。
- 作者认为,在该研究人群中长期处方曲美他嗪未见统计学显著安全性担忧。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Angina might persist or reoccur despite successful revascularisation with percutaneous coronary intervention (PCI) and antianginal therapy. Additionally, PCI in stable patients has not been shown to improve survival compared with optimal medical therapy. Trimetazidine is an antianginal agent that improves energy metabolism of the ischaemic myocardium and might improve outcomes and symptoms of patients who recently had a PCI. In this study, we aimed to assess the long-term potential benefits and safety of trimetazidine added to standard evidence-based medical treatment in patients who had a recent successful PCI.
METHODS: We did a randomised, double-blind, placebo-controlled, event-driven trial of trimetazidine added to standard background therapy in patients who had undergone successful PCI at 365 centres in 27 countries across Europe, South America, Asia, and north Africa. Eligible patients were aged 21-85 years and had had either elective PCI for stable angina or urgent PCI for unstable angina or non-ST segment elevation myocardial infarction less than 30 days before randomisation. Patients were randomly assigned by an interactive web response system to oral trimetazidine 35 mg modified-release twice daily or matching placebo. Participants, study investigators, and all study staff were masked to treatment allocation. The primary efficacy endpoint was a composite of cardiac death; hospital admission for a cardiac event; recurrence or persistence of angina requiring an addition, switch, or increase of the dose of at least one antianginal drug; or recurrence or persistence of angina requiring a coronary angiography. Efficacy analyses were done according to the intention-to-treat principle. Safety was assessed in all patients who had at least one dose of study drug. This study is registered with the EU Clinical Trials Register (EudraCT 2010-022134-89).
FINDINGS: From Sept 17, 2014, to June 15, 2016, 6007 patients were enrolled and randomly assigned to receive either trimetazidine (n=2998) or placebo (n=3009). After a median follow-up of 47·5 months (IQR 42·3-53·3), incidence of primary endpoint events was not significantly different between the trimetazidine group (700 [23·3%] patients) and the placebo group (714 [23·7%]; hazard ratio 0·98 [95% CI 0·88-1·09], p=0·73). When analysed individually, there were no significant differences in the incidence of the components of the primary endpoint between the treatment groups. Similar results were obtained when patients were categorised according to whether they had an elective or urgent PCI. 1219 (40·9%) of 2983 patients in the trimetazidine group and 1230 (41·1%) of 2990 patients in the placebo group had serious treatment-emergent adverse events. Frequencies of adverse events of interest were similar between the groups.
INTERPRETATION: Our results show that the routine use of oral trimetazidine 35 mg twice daily over several years in patients receiving optimal medical therapy, after successful PCI, does not influence the recurrence of angina or the outcome; these findings should be taken into account when considering the place of trimetazidine in clinical practice. However, the long-term prescription of this treatment does not appear to be associated with any statistically significant safety concerns in the population studied.
参考来源
- Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020. PMID: 32877651. doi:10.1016/S0140-6736(20)31790-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。